Skip to main content
. Author manuscript; available in PMC: 2014 Jun 26.
Published in final edited form as: Vaccine. 2013 May 16;31(30):3079–3089. doi: 10.1016/j.vaccine.2013.04.052

Table 3.

First-order SI sensitivity of optimal vaccine allocation to epidemiological parameters of the seasonal influenza model for the five different outcome measures.

Outcome measure
Deaths Years of life loss Contingent value Infections Hospitalizations
Parameter SI Parameter SI Parameter SI Parameter SI Parameter SI
Age group 5–17 Recovery rate ages 0–14 0.51 Recovery rate ages 0–14 0.46 Recovery rate ages 0–14 0.50 Age group 0.5–4 Recovery rate ages 15+ 0.56 Recovery rate ages 15+ 0.52
Recovery rate ages 15+ 0.30 Recovery rate ages 15+ 0.29 Recovery rate ages 15+ 0.28 Recovery rate ages 0–14 0.41 Recovery rate ages 0–14 0.41
Reproductive number (R) 0.10 Reproductive number (R) 0.19 Reproductive number (R) 0.16 Vaccine efficacy (vs infection) ages 0.5–16 0.004 Vaccine efficacy (vs infection) ages 16–65 0.03
Age group 18–44 Recovery rate ages 0–14 0.48 Recovery rate ages 15+ 0.33 Recovery rate ages 0–14 0.41 Age group 5–17 Recovery rate ages 0–14 0.54 Recovery rate ages 0–14 0.54
Recovery rate ages 15+ 0.47 Recovery rate ages 0–14 0.32 Recovery rate ages 15+ 0.35 Recovery rate ages 15+ 0.43 Recovery rate ages 15+ 0.33
Reproductive number (R) 0.03 Reproductive number (R) 0.20 Reproductive number (R) 0.13 Susceptibility ages 5–17 0.013 Reproductive number (R) 0.07
High-risk group Recovery rate ages 15+ 0.41 Reproductive number (R) 0.81 Reproductive number (R) 0.77 Age group 18–44 Recovery rate ages 15+ 0.49 Recovery rate ages 0–14 0.46
Recovery rate ages 0–14 0.30 Vaccine efficacy (vs infection) ages 16–65 0.06 Recovery rate ages 15+ 0.04 Recovery rate ages 0–14 0.48 Recovery rate ages 15+ 0.41
Reproductive number (R) 0.21 Recovery rate ages 15+ 0.03 Vaccine efficacy (vs infection) ages 16–65 0.03 Susceptibility ages 5–17 0.006 Vaccine efficacy (vs infection) ages 16–65 0.08

The first-order sensitivity index (SI) was used to determine the contribution of input parameters to the variability of the optimal proportions of individuals vaccinated per group. The analysis only considered groups with sufficient variability in the distribution of the optimal proportion of vaccinated individuals (Figure 1). The amount of vaccine was 80M doses.